Orphan Drug Status was recently granted to an experimental compound, AEOL 10150, under development by Aeolus Pharmaceuticals to address the need for novel treatments for idiopathic pulmonary fibrosis. AEOL 10150 is a broad-spectrum catalytic antioxidant thought to neutralize reactive nitrogen and oxygen species and, consequently, reduce inflammation, oxidative stress and subsequent…
Aeolus’ Idiopathic Pulmonary Fibrosis Compound Gets Orphan Drug Status
Belgian based biotech firm Galapagos, a company that specializes in the discovery and development of molecular medicines with new drug targets, announced that its seven year proprietary investment agreement with Janssen Pharmaceuticals, part of the Johnson & Johnson healthcare brand, has been terminated by mutual agreement between the two…
The Pulmonary Fibrosis Foundation (PFF) recently announced the expansion of the Leanne Storch Support Group Fund, designed to assist PFF in its support group experience with individuals with PF and their families and positively impact the pulmonary fibrosis community. In part through generous funding from Boehringer Ingelheim, the…
The independent, non-profit HealthWell Foundation is launching a new fund dedicated to supporting patients who suffer from pulmonary fibrosis. The main mission of the foundation is to offer financial help to underinsured people in the United States in order to improve their access to life-changing medical treatments.
ndd Medical Technologies, a top firm in innovative mobile pulmonary function testing (PFT) that utilizes precise ultrasound mechanisms, recently announced that the company’s EasyOne Pro® was used at a free clinic event held by the San Antonio Pulmonary Fibrosis Support Group. The patients targeted by the clinic were those with…
A registry study called the “Pulmonary Fibrosis Contract Registry” is being conducted by the Pulmonary Fibrosis Foundation in collaboration with the Patient Centered Outcome Research Institute (ClinicalTrials.gov Identifier: NCT01935726) This is an observational prospective study that will run for 20 years with the goal of…
A phase III clinical trial sponsored by the Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (FISEVI) in Spain is currently recruiting participants to enroll in a study designed to assess the efficacy of idiopathic pulmonary fibrosis (IPF) treatment, cotrimoxazole (TriSulfa-FPI). The study is entitled “…
A recent report on Research and Markets covered this year’s featured companies’ Pipeline Therapeutics for the annual Pulmonary Fibrosis Review. The report details descriptions of 56 companies currently developing treatment strategies for therapeutics for Pulmonary Fibrosis. The team conducted comparative analysis of the companies’ compounds under clinical investigation at various stages, and…
A new study published in the March 3 issue of the Journal of the American Medical Association (JAMA) finds that a medical need-based donor lung allocation protocol has been associated with better graft survival than single-lung transplantation procedures in persons afflicted with idiopathic pulmonary fibrosis (IPF). The…
(Back row, left to right) Broadway Belts for PFF! cast members, Julia Murney, Randy Graff, Julie Halston, Erich Bergen, Zakiya Young, Betsy Wolfe (Front row, left to right) Bobby Creighton, Annaleigh Ashford, Santino Fontana. The Tony award-winning cast performed at the Broadway Belts for PFF! fundraiser to…
